IP Library Granted Patent US 7,192,781
Granted Patent B2
US 7,192,781 · App. 10/823,394 · Granted Mar 20, 2007

Methods for stabilizing 5-azacytidine in plasma

Assignee: Pharmion Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,192,781
App. No.
10/823,394
Granted
Mar 20, 2007
Kind
B2
Abstract

The invention provides methods for stabilizing 5-azacytidine against hydrolysis in plasma. By extracting the 5-azacytidine into acetonitrile and zinc sulfate, the 5-azacytidine can be stored for at least about 3 hours at about room temperature, and for at least about 4 days at about −70° C. If the acetonitrile is removed and evaporated to dryness, the 5-azacytidine in the resulting residue is stable for at least about 14 months at about −70° C. The invention also provides methods for determining the 5-azacytidine in acetonitrile, or in the acetonitrile residue, using, for example, high-performance liquid chromatography. The methods of the invention permit a significant time interval between the initial processing of the whole blood sample and the time of 5-azacytidine determination.

Claims (24)

1. A method for preparing a sample of plasma containing 5-azacytidine for quantitative analysis of said 5-azacytidine, the method comprising:

a) mixing said plasma with acetonitrile and zinc sulfate;

b) separating the mixture from step a) by centrifugation; and

c) storing the centrifuged mixture from step b) at a temperature less than or equal to about room temperature for at least about 3 hours.

2. The method of claim 1 , wherein the ratio of plasma to acetonitrile/zinc sulfate solution in step (a) is less than or about equal to 1:20 (v/v).

3. A method for quantitating 5-azacytidine in plasma comprising:

a) mixing said plasma with acetonitrile and zinc sulfate;

b) separating the mixture from step a) into an acetonitrile layer and a plasma layer by centrifugation;

c) storing the centrifuged mixture from step b) at a temperature less than or equal to about room temperature for at least about 3 hours; and

d) measuring the amount of 5-azacytidine in said acetonitrile layer using high-performance liquid chromatography.

4. The method of claim 3 , wherein the ratio of plasma to acetonitrile/zinc sulfate solution in step (a) is less than or about equal to 1:20 (v/v).

5. A method for preparing a sample of plasma containing 5-azacytidine for quantitative analysis of said 5-azacytidine, the method comprising:

a) mixing said plasma with acetonitrile and zinc sulfate;

b) separating the mixture from step a) into an acetonitrile layer and a plasma layer by centrifugation;

c) removing at least a portion of said acetonitrile layer; and

d) evaporating said removed acetonitrile layer to yield a residue comprising 5-azacytidine.

6. A method for quantitating 5-azacytidine in plasma comprising:

a) mixing said plasma with acetonitrile and zinc sulfate;

b) separating the mixture from step a) into an acetonitrile layer and a plasma layer by centrifugation;

c) removing at least a portion of said acetonitrile layer;

d) evaporating said removed acetonitrile layer to yield a residue comprising 5-azacytidine; and

e) measuring the amount of 5-azacytidine in said residue.

7. The method of claim 6 wherein the residue of step d) is stored at about minus 70° C. for between about 3 hours and about 14 months prior to step e).

8. The method of claim 6 wherein 5-azacytidine is measured in step e) using high-performance liquid chromatography with mass spectrometric detection.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY PREVIOUSLY RECORDED ON REEL 022482 FRAME 0435. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jul 27, 2010
From: PHARMION CORPORATION
To: PHARMION LLC
Reel/Frame 024741/0631 →
MERGER Recorded Apr 1, 2009
From: PHARMION CORPORATION
To: CELGENE CORPORATION
Reel/Frame 022482/0435 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2004
From: LUNA, MARSHA; BURMASTER, STEVE; EDEN, LARRY
To: PHARMION CORPORATION
Reel/Frame 015406/0798 →
Continuity (1)
Related Publication 20050227367A1 · Oct 13, 2005